MARLBOROUGH, Mass., June 8, 2017 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet medical needs, announced today that its President and CEO, Dr. Geert Cauwenbergh will present at the Marcum MicroCap Conference being held in New York City. Dr. Cauwenbergh will present a corporate overview that includes its proprietary self-delivering RNA (sd-rxRNA®) therapeutic platform and the Company's ongoing research and clinical programs in cell-based immunotherapy, dermatology, and ophthalmology.
This event provides a platform for smaller entrepreneurial public companies with less than $500M in market capitalization to present to and meet with institutional investors, venture and lower middle-market private equity investors and buy- and sell-side analysts. The conference is being held on June 15-16, 2017 at the Grand Hyatt Hotel in NYC.
- RXi Pharmaceuticals presentation at the Marcum MicroCap Conference
June 15, 2017 at 4:00pm ET, Morosco Room
Geert Cauwenbergh, Dr. Med. Sc., President and CEO, RXi Pharmaceuticals
The presentation will be available under the "Investors – Events and Presentations" section of the Company's website, www.rxipharma.com approximately 1 hour following the presentation.
About RXi's Proprietary Self-delivering RNAi (sd-rxRNA) Technology Platform
Building on the pioneering discovery of RNAi, scientists at RXi have harnessed the naturally occurring RNAi process which has the ability to "silence" or down-regulate the expression of a specific gene that may be overexpressed in a disease condition. The Company developed a robust RNAi therapeutic platform that includes self-delivering RNAi (sd-rxRNA) compounds that have the ability to highly selectively block the expression of any target in the genome, thus providing applicability to a broad spectrum of therapeutic areas. This proprietary sd-rxRNA technology has many advantages over its competitors in the RNAi space because of built-in delivery properties and no requirement of a delivery vehicle for local therapeutic applications. sd-rxRNA compounds are chemically-modified RNAi compounds with improved drug-like properties that are potent, stable and specific. The enhanced properties of sd-rxRNA include: efficient spontaneous cellular uptake, stability, reduced potential for immune stimulation, and potent, long-lasting intracellular activity. All cell types tested (primary, neuronal and non-adherent) internalize sd-rxRNA compounds uniformly and efficiently, resulting in potent and long lasting silencing.
About RXi Pharmaceuticals
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a clinical-stage company developing innovative therapeutics that address significant unmet medical needs. Building on the pioneering discovery of RNAi, scientists at RXi have harnessed the naturally occurring RNAi process which has the ability to "silence" or down-regulate the expression of a specific gene that may be overexpressed in a disease condition. RXi developed a robust RNAi therapeutic platform including self-delivering RNA (sd-rxRNA) compounds that have the ability to highly selectively block the expression of any target in the genome, thus providing applicability to many therapeutic areas. Our current programs include dermatology, ophthalmology and cell-based immunotherapy. RXi's extensive patent portfolio provides for multiple product and business development opportunities across a broad spectrum of therapeutic areas and we actively pursue research collaborations, partnering and out-licensing opportunities with academia and pharmaceutical companies. Additional information may be found on the Company's website, www.rxipharma.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about: our ability to successfully develop RXI-109, Samcyprone™ and our other product candidates (collectively "our product candidates"); the future success of our clinical trials with our product candidates; the timing for the commencement and completion of clinical trials; our ability to enter into strategic partnerships and the future success of these strategic partnerships; and our ability to deploy our sd-rxRNA® technology through partnerships, as well as the prospects of these partnerships to provide positive returns. Forward-looking statements about expectations and development plans of RXi's product candidates and partnerships involve significant risks and uncertainties, including the following: risks that we may not be able to successfully develop and commercialize our product candidates; risks that product development and clinical studies may be delayed, not proceed as planned and/or be subject to significant cost over-runs; risks related to the development and commercialization of products by competitors; risks related to our ability to control the timing and terms of collaborations with third parties; and risks that other companies or organizations may assert patent rights preventing us from developing or commercializing our product candidates. Additional risks are detailed in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors." Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. RXi does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.
RXi Pharmaceuticals Corporation
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/rxi-pharmaceuticals-to-present-at-the-marcum-microcap-conference-300470833.html
SOURCE RXi Pharmaceuticals Corporation